| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2015: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
|
|---|
| Outline of Final Research Achievements |
We evaluated the safety of conjunctival rings (CR), a novel device for drug delivery to the posterior segment of the eye. Our data demonstrated that CR is safe for use in vivo. The use of CR has the advantage of avoiding several side effects that are associated with the existing implant devices, since removing the device from the ocular surface easily discontinues the drug therapy. Therefore, CR could be a new drug delivery device and safe approach in the treatment of posterior segment diseases such as age-related macular degeneration, diabetic macular edema and uveitis.
|
